S&P Futures
3,367.00-3.00(-0.09%)Dow Futures
27,853.00-13.00(-0.05%)Nasdaq Futures
11,108.00-18.00(-0.16%)
Catalent, Inc. (CTLT)
Chart Events
Performance Outlook
| Previous Close | 84.90 |
| Open | 85.68 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1400 |
| Day's Range | 85.11 - 88.18 |
| 52 Week Range | 31.04 - 91.18 |
| Volume | 717,305 |
| Avg. Volume | 1,465,101 |
| Market Cap | 14.383B |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | 126.51 |
| EPS (TTM) | 0.69 |
| Earnings Date | Aug 31, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 93.67 |
Fair Value
Related Research
- Insider Monkey
Catalent (CTLT) is a Critical Partner to Develop COVID-19 Vaccine
Brown Advisory recently released its Q2 2020 Investor Letter, a copy of which you can download here. The Small-Cap Growth Fund posted a return of 34.59% for the quarter, outperforming its benchmark, the Russell 2000 Growth Index which returned 30.59% in the same quarter. You should check out Brown Advisory’s top 5 stock picks for […]
- Investor's Business Daily
How Top Fund Managers Spot Tomorrow's Stock Winners Early
Federated Hermes Kaufmann Small Cap is one of the best mutual funds as it gets in early on innovative small-company stocks with big potential.
- Business Wire
Catalent, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Fiscal Year 2020 Net Revenue, Earnings Before Income Taxes, and Adjusted EBITDA Significantly Ahead of Its Previous Guidance
Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that, given the fluidity created by the COVID-19 pandemic and level of uncertainty at the time when Catalent last provided financial guidance on May 5, 2020, it is providing certain preliminary financial results for the fourth quarter and full fiscal year, both of which ended June 30, 2020, including net revenue, earnings before income taxes, and Adjusted EBITDA (see the non-GAAP reconciliation elsewhere in this release for a discussion of Adjusted EBITDA).
